Keryx Licenses Japanese Rights For Zerenex To Japan Tobacco In $100 Million Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Keryx CEO says the novel phosphate binder has advantages over treatments such as Genzyme’s Renagel.